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Current available secondary dose calculation software for Gamma Knife radiosurgery
falls short in situations where the target is shallow in depth or when the patient is
positioned with a gamma angle other than 90°. In this work, we evaluate a new sec-
ondary calculation software which utilizes an innovative method to handle nonstan-
dard gamma angles and image thresholding to render the skull for dose calculation.
800 treatment targets previously treated with our GammaKnife Icon system were
imported from our treatment planning system (GammaPlan 11.0.3) and a secondary
dose calculation was conducted. The agreement between the new calculations and
the TPS were recorded and compared to the original secondary dose calculation
agreement with the TPS using a Wilcoxon Signed Rank Test. Further comparisons
using a Mann‐Whitney test were made for targets treated at a 90° gamma angle
against those treated with either a 70 or 110 gamma angle for both the new and
commercial secondary dose calculation systems. Correlations between dose devia-
tions from the treatment planning system against average target depth were evalu-
ated using a Kendall’s Tau correlation test for both programs. The Wilcoxon Signed
Rank Test indicated a significant difference in the agreement between the two sec-
ondary calculations and the TPS, with a P‐value < 0.0001. With respect to patients
treated at nonstandard gamma angles, the new software was largely independent of
patient setup, while the commercial software showed a significant dependence (P‐
value < 0.0001). The new secondary dose calculation software showed a moderate
correlation with calculation depth, while the commercial software showed a weak
correlation (Tau = −.322 and Tau = −.217 respectively). Overall, the new secondary
software has better agreement with the TPS than the commercially available sec-
ondary calculation software over a range of diverse treatment geometries.
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1 | INTRODUCTION
Gamma Knife (GK) radiosurgery has become a popular technique for
the treatment of a variety of intracranial diseases, such as acoustic
neuroma, pituitary adenoma, trigeminal neuralgia, vascular malforma-
tions, and malignant metastases.1,2 Using 192 collimated Co‐60
sources focused at an isocenter, a patient will be stereotactically
positioned to place the target at the source ray intersections to sub-
millimeter accuracy.3 GK treatments are characterized by large doses
delivered in a single, or more recently, hypofractionated schemes uti-
lizing rigid thermoplastic masks with cone beam CT image guidance,
and very sharp dose gradients outside of the target.4,5 Because of
the uniqueness of this system and treatments, quality assurance
(QA) is of the utmost importance, including patient specific sec-
ondary dose calculations.6 Secondary independent dose calculations
play an important role in radiation therapy, and given the high preci-
sion associated with GK radiosurgery, secondary dose checks
become even more important to reduce the risk of doing serious
harm to the patient.7,8
Given the complicated geometry of GK treatments, establishing
an accurate methodology to incorporate secondary dose calcula-
tions into the clinic workflow has been cumbersome.8 There have
been several publications working to satisfy this clinical need, but
many of the secondary dose calculation techniques suggested will
still fail in certain situations, most notably when the patient is
setup with a 110 or 70° gamma angle, or when the calculation
point is at a shallow depth near the skull surface. It has been sug-
gested that these difficulties in accurate secondary dose calcula-
tion arise from modeling the skull geometry, and constant density
assumptions near the skull surface.8 Different skull rendering tech-
niques have been proposed, including modeling the skull as a
sphere or using measured skull data from the use of a skull scalar
instrument.8–10 These methods work well for standard patient and
target geometries, but significant discrepancies from the treatment
planning system (TPS) are still evident when the target is at a
shallow depth or when the patient setup uses a non 90° gamma
angle.11 It has been suggested that using an image thresholding
technique may be the best method to accurately construct the
patients skull for dose calculation.12 Image thresholding makes use
of an image data set such as CT or MRI and binarily assigns a
voxel of the dataset to be within or beyond the skull boundary
based upon a determined threshold image scale value. Skull ren-
dering using this method minimizes uncertainties from measure-
ment interpolation and produces an accurate representation of the
true patient surface geometry.
Our institution installed the Leksell Gamma Knife Icon (Elekta
Medical Systems, Stockholm, Sweden) in November of 2017. The
Icon treatment system utilizes 192 Co‐60 sources divided into eight
sectors that can be individually blocked, or collimated to 4, 8, and
16 mm shot sizes. The Icon is unique in that it utilizes on‐board cone
beam computed tomography (CBCT) imaging system to enable frac-
tionated and frameless treatments.13 The specifics on commissioning
and QA for the Icon system can be found in the literature.13–16 Dose
is calculated for Icon patients using the TMR10 algorithm.17 This
algorithm requires only dose rate calibration given by the user and a
configurable collimator output factors that are provided by manufac-
turer. The TMR10 uses an exponential attenuation computation to
the point of interest that is specific to each source location. The
attenuation length (i.e. depth of the point of interest in the patient)
for each source is calculated based on the source focal point, the
distance from the focal point to the point of interest, and the dis-
tance to the rendered skull surface.18 For each GK Icon target trea-
ted, a secondary dose calculation using a commercially available
software is completed prior to treatment per institution policy. This
commercial secondary check software reportedly uses the same
TMR10 dose calculation formalism as the TPS, and reconstructs the
patient skull using 24 scalar measurements either input directly by
the user or inferred from a CT dataset.19 The same user inputs were
utilized for the second check software as the TPS. Our experience is
similar to Xu et al.,11 especially where the commercially available
software performs poorly in the presence of a nonstandard gamma
angle, in some cases deviating from the TPS by more than 10%. This
known issue presents a clinical difficulty in that treatment cannot
proceed unless the TPS and secondary dose calculation agree to
within 5%, as is the recommendation taken from AAPM Task Group
40 and our clinical policy.7 In many cases, the problem is circum-
vented by selecting a different point in the plan other than the point
of maximum dose for comparison. Unfortunately, this limits the
applicability of the integral purpose of independent secondary dose
calculation.
In this work, a new secondary dose calculation engine based on
the work of Mamalui‐Hunter et al.12 is evaluated and compared to a
commercially available secondary check software. The new software
reportedly uses the same dose calculation algorithm as described
previously,20 but aims to solve the described deficiencies of previous
secondary dose calculation methods. An image threshold skull ren-
dering technique is utilized, and the gamma angle is precisely
accounted for by applying a rotation matrix for each beamlet directly
in the new software. Beamlets are created at each source position
for each shot in each target. The beamlets themselves are then
rotated and translated in space according to shot geometry, including
gamma angle considerations. With the beamlets in their proper geo-
metric positions about the skull, the vectors from source to isocenter
and calculation point are ray traced through patient geometry for
depth calculations to compute dose.
The combination of these two methods may result in more accu-
rate calculation conditions for both standard and nonstandard
gamma angles which in turn will provide a more robust secondary
calculation engine that can be used in the clinical setting.
2 | MATERIALS AND METHODS
To evaluate the new secondary dose calculation software (Radcalc,
Lifeline Software, Austin, TX) after the review and approval from the
Institutional Review Board (HRPO# 201904138), the first 800
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targets treated since the Icon’s installation at our institution were
exported from our treatment planning software (TPS) (GammaPlan
11.0.3, Elekta Medical Systems, Stockholm, Sweden) to the new sec-
ondary calculation patient database. These 800 targets were a suffi-
cient representative of the patient population that is typically
treated at our institution. Target positions ranged from the periphery
of the skull to more central locations. This resulted in a wide range
of average calculation depths, from 2.4 to 10.5 cm. The target popu-
lation used in this study also included a variety of non‐standard
patient setup geometries where a gamma angle of 70 or 110° was
utilized (30 cases).
After each target was imported into the new secondary calcula-
tion software, the patient skulls were constructed using the image
thresholding technique, in contrast with the derived scalar measure-
ments used in the commercial software (Gamma Check, MU Check,
Oklahoma City, OK), available with the program (Fig. 1). In most
cases, the skulls were rendered from a CT image dataset. However,
in approximately 10% of the patient plans a CT dataset was not
available and the patient’s skull was rendered using an MRI dataset.
The current versions of the TPS support image thresholding skull
definition from both types of imaging modalities. Individual beamlet
rotations were also made for patient setups using non‐standard
gamma angles. Dose was re‐calculated with the new software, and
the agreement to the TPS was evaluated. This was done using the
percent difference for each individual target. The median and range
of the percent differences per target was calculated over the entire
cohort. A further comparison of deviation between TPS and sec-
ondary calculation doses with respect to average calculation depth
was completed using a Kendall’s Tau correlation test to evaluate any
dependencies the secondary software has on target location depth
in the skull. The target cohort was then binarily categorized by
gamma angle (standard 90° and nonstandard 70/110°). Using a
Mann‐Whitney U test, differences between the two categories with
respect to agreement with the TPS were evaluated for statistical sig-
nificance.
A Wilcoxon Signed Rank Test (WSRT) was used to evaluate sig-
nificant differences in the deviation from the TPS calculated dose
over the entire 800 treatment targets for both calculation software
packages. Using the same techniques as described for the new sec-
ondary dose calculation software, dependencies on agreement to the
TPS of the commercially available software dose calculation as it
pertains to gamma angle and average calculation depth were evalu-
ated and compared to the dependencies of the new secondary dose
calculation software.
The new secondary dose calculation software has the capabil-
ity to render the skull for dose calculation using discrete scalar
measurements if these measurements were used in the TPS for
planning. To isolate the robustness of the beamlet rotation
algorithm employed for nonstandard gamma angles by the new
software, the target with a nonstandard gamma angle patient
setup that showed the largest discrepancy from the TPS by the
commercially available software was replanned in GammaPlan
using skull scalar measurements. The plan was reimported to the
new software and the skull was rendered using the discrete mea-
surements. Dose was recalculated using the new software and
compared with the TPS.
F I G . 1 . Top: A reconstructed phantom
skull surface geometry using the image
thresholding technique from the new
secondary calculation software for a head
phantom. Bottom: A reconstructed
phantom skull surface geometry using
scalar measurements from the commercial
software.
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As the purpose for a secondary dose calculation is to give the
user confidence that the primary dose calculation from the TPS is
accurate, an absolute dose measurement was also employed for
comparison against both the TPS and the two secondary dose calcu-
lation engines. In the two plans where the TPS estimated dose and
the commercially available secondary dose software differed the
greatest, the shot arrangement and gamma angle in the patient plan
was copied to an anthropomorphic phantom and a film measurement
was taken. Using EBT3 gafrchormic film cross calibrated to an ADCL
calibrated ionization chamber, an optical density to dose calibration
curve was created by irradiating a 16 mm shot to 2, 3, 4 and 5 Gy.
Next, the patient plan was scaled to a max dose of 4 Gy, and deliv-
ered on an anthropomorphic head phantom. The maximum measured
dose was then compared to the TPS, a calculation from commercially
available software, and what the new secondary dose calculation
software predicted. Each of the film measurements, including calibra-
tion films, were repeated three times.
3 | RESULTS
Over the entire target cohort, the new secondary dose calculation
software showed excellent agreement with the TPS. The differences
from the TPS ranged from 0.00% to 3.33%, with a median and mean
value of 0.6% and 0.68%, respectively, which is well within our clini-
cal tolerance. The agreement between the TPS and the commercially
available dose calculation software showed larger deviations, ranging
from 0.00% to 10.25% and a median and mean value of 0.833% and
1.15%, with 13 above clinical tolerance. These data are shown in
Fig. 2. The WSRT revealed a significant difference in the agreement
deviations between the new and commercially available secondary
dose calculations, with a P‐value < 0.0001, where the overall agree-
ment between the new secondary dose calculation software and the
TPS was superior as shown in Fig. 3.
With respect to the secondary dose calculation dependency on
average calculation depth, the Kendall’s Tau correlation test showed
that a moderate (tau = −.322), and weak (tau = −.217) inverse corre-
lation exists between calculated dose discrepancy from the TPS and
calculation depth for the new secondary dose calculation software
and the commercially available software, respectively, shown in
Fig. 4. This suggests that for the new secondary dose calculation
software, the discrepancy in calculated dose from the TPS may
increase slightly for targets at shallower depth, however, for the
commercial software the depth does not seem to correlate well with
percent difference.
The gamma angle does not appear to play a large role in the cal-
culated dose agreement between the new secondary dose calcula-
tion software and the TPS. When compared to dose deviations from
the TPS at a gamma angle of 90°, the discrepancies from the TPS at
gamma angles of 70/110° were not significant (P‐value = 0.102). This
is in contrast with what was seen with the commercially available
calculation software, where the discrepancies between dose calcula-
tions were significant for standard vs nonstandard gamma angles
(P < 0.0001), shown in Fig. 5. When looking at dose deviations for
gamma angles of 90° only, the new secondary calculation software
showed significantly smaller deviations from the TPS when com-
pared to the commercial software (P < 0.0001).
The largest deviation from the TPS calculated dose using the
commercially available secondary software was 10.25%. This particu-
lar plan had a nonstandard gamma angle of 70°. The corresponding
F I G . 2 . The absolute percent differences from the TPS for each of the 800 targets calculated using the new secondary dose check software
and the commercially available secondary dose calculation software. TPS, treatment planning system.
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point with the new check software using image threshold skull ren-
dering was 1.3 percent. The new secondary calculation software has
the capability to construct the skull for calculation using scalar mea-
surements, assuming the skull was constructed this way in the TPS.
To isolate how the two secondary calculation engines compare to
the TPS when both use scalar measurements for skull rendering, this
plan was recalculated in Gamma Plan with skull scalar measurements
(as opposed to an image dataset) and a secondary dose check was
repeated using both systems. When recalculated in the new soft-
ware using skull scalar measurements the agreement remained
within clinical tolerance at 0.1%, the corresponding agreement using
the commercial software was still above tolerance at 6.5%.
In the two cases where the commercial secondary calculation
and the TPS differed the greatest, one target utilized a gamma angle
of 70° in the plan, while the other had a gamma angle of 110°.
When these target plans were replanned on the anthropomorphic
phantom to a maximum dose of 4 Gy, the commercial and new sec-
ondary dose calculated a max dose of 4.36 Gy (9.2% higher than the
TPS) and 4.047 Gy (1.2% higher than the TPS) for the 70° gamma
angle plan and 4.39 Gy (9.1% higher than the TPS) and 4.044 Gy
(1.1% higher than the TPS) for the 110° gamma angle plan. How-
ever, the film measurement resulted in a delivered dose of 3.91 Gy
+/− 0.04 Gy to the 70° gamma angle plan differing from the TPS by
−2.25%, and 3.88 Gy +/− 0.08 Gy to the 110° plan, differing from
F I G . 3 . A box and swarm plot of the
absolute differences from the TPS and the
Wilcoxon Signed Rank Test for each of the
800 targets using the commercial and new
secondary dose calculation software. TPS,
treatment planning system.
F I G . 4 . The results of the Kendall’s tau correlation evaluation. The absolute percent difference from the TPS for the new software shows a
moderate correlation with average calculation depth (tau = −0.322). The absolute percent difference from the TPS for the commercial software
shows a weak correlation with average calculation depth (tau = −0.217). TPS, treatment planning system.
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the TPS by −3%. Both the TPS and new secondary dose calculation
fall well within our clinic’s 5% agreement criteria with measurement,
while the commercial secondary calculation falls well outside of the
measurement results.
4 | DISCUSSION
The results from this study show promising clinical applicability for
the new secondary dose calculation software. Each of the 800 tar-
gets calculated are well within our clinical tolerance of 5%. The dis-
tribution of deviations from the TPS between the commercial
software and the new calculation software shows a significant differ-
ence, with the deviations being smaller for the new software. This
shows strong evidence that the new secondary dose calculation soft-
ware is a robust platform for independent dose calculation that
effectively handles complex patient setup and geometries. This is
especially true when considering the use of nonstandard gamma
angles for patient positioning. The commercially available software
falls short in several instances where a gamma angle of 70 or 110°
is used. In fact, the Mann‐Whitney test shows a significant differ-
ence in the deviations from the TPS between standard and nonstan-
dard gamma angles for the commercially available secondary dose
calculation software, confirming dependency on the patient orienta-
tion that has been previously shown in literature.11 However, the
same comparison is not significant for the new secondary dose cal-
culation software, indicating that the method of beamlet rotation
matrices eliminates this dependence. This argument is further
strengthened by the skull scalar measurement example using the
new calculation software, as well as by the absolute film dose mea-
surement. In skull scalar measurement example, both the commer-
cially available and secondary dose software rendered the skull using
skull scalar measurements, removing the dependency on the render-
ing of the skull and isolating the methods used by these two pro-
grams to handle gamma rotations. The new software calculation was
still well within tolerance, while the commercial software showed a
discrepancy of 6.5%. With regards to measurement, for the cases
where the commercial software disagrees significantly from the TPS,
the new software does agree well within tolerance to the TPS and
absolute film dose measurement. This suggests that while the new
software agrees well with the TPS, it is also independently accurate
in calculating dose for complex treatment plans where nonstandard
gamma angles are used in patient setup.
The gamma rotation technique of the commercial software is rela-
tively unclear. The information on this topic available to the user via
vendor provided documentation provides a short summary for the
Gamma Knife model 4C, but gives little insight for the Icon.19 Based
upon this documentation it appears that for the 4C, the general strat-
egy of translating source position with respect to gamma angle is sim-
ilar to the new software. However, the implementations of the
beamlet translation algorithm for the Icon used by the two different
secondary calculation engines are not equivalent. This is apparent
when looking at the profiles of each 16 mm shot in the X, Y, and Z
directions for each gamma angle. Figure 6 shows a comparison of the
dose profiles taken from the TPS, the commercial software, and the
new software in each plane and for gamma angles of 70, 90, and
110°. When looking at the comparison for 90° gamma angle, the
agreement between the three dose calculations is exceptional. How-
ever, at the nonstandard gamma angles, there are large discrepancies
in the penumbra and tail regions of the profiles. In the X direction,
the commercial software significantly underpredicts the dose when
compared to the new software and the TPS. In the Y direction, the
commercial profile is asymmetric compared to the other two calcula-
tions, where one side of the profile matches reasonably well, and the
opposite side calculates a lower dose in comparison. In the Z direc-
tion, the commercial software overpredicts dose compared to the
other two calculation algorithms. However, in all three planes for
each gamma angle setup, the profiles of the new software and the
TPS agree well. It is likely that for this reason large discrepancies from
the TPS dose calculations are seen in the commercial software but
not the new secondary dose calculation software. When two or more
shots are in close proximity with nonstandard gamma angles, the
propagation of errors in the tail regions of the profiles compounding
on the high dose area of another shot will cause a large disagreement
between the two calculations that is not seen with the new sec-
ondary dose calculation software.
F I G . 5 . The comparison of percent
differences with regards to standard and
non‐standard gamma angle setups for both
the commercial software and the new
software. The new software does not
show a significant dependency on gamma
angle in patient setup (P = 0.1025).
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Looking at the calculations for patients treated at 90° gamma
angles only, the new secondary software had significantly
(P < 0.0001) smaller deviations from the TPS than the commercial
software. This indicates that the imaging threshold method of skull
rending out performs scalar measurements with interpolation, sug-
gesting that a patient’s head may not always be well‐described by
24 scalar measurements. Rendering the skull using this image thresh-
olding technique gives much more flexibility for accurate calculation
over a wide range of skull shapes and sizes.
While the new software showed excellent agreement with the
TPS and measurement, the calculation deviation does appear to have
a small dependence on the average calculation depth, as shown by
the moderate correlation in the Kendall Tau test. It is not obvious as
to what the source of this dependency is, but it could be a function
of interpolation in the 3D computation matrix to a single point dose
that is more evident at shallower depths. However, in the commer-
cial software depth showed a weak correlation to the agreement
with the TPS. This result did not support the previous suggestions in
the literature that the depth of the target is a driving factor in the
accuracy of the secondary dose calculation. However, this work did
show a strong dependency for the commercial software on the
gamma angle as suggested in the literature.
5 | CONCLUSION
Currently, secondary dose calculation in Gamma Knife radiosurgery
is not robust and current methods of computing dose accurately
depend on the simplicity of treatment geometry. In complex patient
setups, these current secondary calculation methods fail, leading the
user to make difficult clinical decisions on whether to proceed with
treatment that may not be warranted due to the inaccuracy of sec-
ondary dose calculation. In this study, a new secondary dose calcula-
tion software for Gamma Knife radiosurgery using image threshold
skull rendering and beamlet rotation technique was evaluated and
compared to a commercially available software for 800 targets trea-
ted with our Icon system. The new software clearly excels where
the commercial software falls short, especially in the presence of
110 and 70° gamma angles in patient setup. This will make a large
impact for the Gamma Knife physicist for plan QA by providing con-
fidence to the user that the planned dose calculated by the TPS is
accurate, regardless of complexity of calculation geometry.
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